Neuropeptide Y and reserpine‐resistant vasoconstriction evoked by sympathetic nerve stimulation in the dog skeletal muscle

1 The effects of sympathetic nerve stimulation (evoked by recordings of authentic irregular vasoconstrictor nerve fibre discharge with average frequencies of 0.59, 2.0 and 6.9 Hz) on the perfusion pressure and the overflow of noradrenaline (NA) and neuropeptide Y‐like immunoreactivity (NPY‐LI) were investigated in the blood‐perfused gracilis muscle of the dog in situ. 2 Nerve stimulation in the untreated control group evoked a frequency‐dependent increase in perfusion pressure and overflow of NA. A significant overflow of NPY‐LI was found at the highest frequency only. 3 In a separate group of animals, the sympathetic supply was unilaterally interrupted by preganglionic decentralization before the administration of reserpine (1 mg kg−1 i.v.) 24 h before the experiment. Reserpine reduced the NA content of the intact and decentralized gracilis and gastrocnemius muscle by 98–99%. Reserpine also induced a marked (80%) reduction of the muscular content of NPY‐LI. The depletion of NPY‐LI was, in contrast to that of NA, prevented by the decentralization, suggesting that nerve impulse activity was of primary importance for the reserpine‐induced depletion of NPY‐LI. 4 A slowly developing and long‐lasting perfusion pressure increase was evoked by nerve stimulation, at 2.0 and 6.9 Hz after reserpine treatment. These responses were larger in the decentralized, as compared to the intact gracilis muscle and correlated with the nerve stimulation evoked overflow of NPY‐LI (r = 0.79, P < 0.001). Stimulation at 0.59 Hz caused vasoconstriction in the decentralized but not in the intact gracilis. 5 Administration of α,β‐methylene adenosine triphosphate did not evoke an increase in perfusion pressure in the gracilis muscle of reserpine‐treated animals. 6 In conclusion, a large perfusion pressure increase to sympathetic nerve stimulation occurs in the reserpine‐pretreated skeletal muscle vasculature of the dog in vivo, providing that preganglionic decentralization has been performed. It is suggested that the released NPY‐LI may mediate this vasoconstrictor response.

[1]  T. Kahan,et al.  Prejunctional beta 2-adrenoreceptor blockade reduces nerve stimulation evoked release of endogenous noradrenaline in skeletal muscle in situ. , 1987, Acta physiologica Scandinavica.

[2]  G. Fried,et al.  Neuropeptide Y and noradrenaline mechanisms in relation to reserpine induced impairment of sympathetic neurotransmission in the cat spleen. , 1987, Acta physiologica Scandinavica.

[3]  I. Muramatsu The effect of reserpine on sympathetic, purinergic neurotransmission in the isolated mesenteric artery of the dog: a pharmacological study , 1987, British Journal of Pharmacology.

[4]  L. Kaijser,et al.  Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. , 1987, Life sciences.

[5]  G. Burnstock,et al.  A pharmacological study of the rabbit saphenous artery in vitro: a vessel with a large purinergic contractile response to sympathetic nerve stimulation , 1987, British journal of pharmacology.

[6]  J. Kelly,et al.  Effect of reserpine, phenoxybenzamine and cold stress on the neuropeptide Y content of the rat peripheral nervous system , 1986, Neuroscience.

[7]  E Theodorsson-Norheim,et al.  Kruskal-Wallis test: BASIC computer program to perform nonparametric one-way analysis of variance and multiple comparisons on ranks of several independent samples. , 1986, Computer methods and programs in biomedicine.

[8]  A. Sollevi,et al.  Frequency- and reserpine-dependent chemical coding of sympathetic transmission: Differential release of noradrenaline and neuropeptide Y from pig spleen , 1986, Neuroscience Letters.

[9]  A. Franco‐Cereceda,et al.  Mechanisms underlying changes in the contents of neuropeptide Y in cardiovascular nerves and adrenal gland induced by sympatholytic drugs. , 1985, Acta physiologica Scandinavica.

[10]  J. Lundberg,et al.  Radioimmunoassay for neuropeptide Y (NPY): chromatographic characterization of immunoreactivity in plasma and tissue extracts. , 1985, Scandinavian journal of clinical and laboratory investigation.

[11]  P. Hjemdahl,et al.  Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle. , 1984, Acta physiologica Scandinavica.

[12]  J. Pernow,et al.  Guanethidine-sensitive release of neuropeptide Y-like immunoreactivity in the cat spleen by sympathetic nerve stimulation , 1984, Neuroscience Letters.

[13]  G. Burnstock,et al.  ATP as a co-transmitter in rat tail artery. , 1984, European journal of pharmacology.

[14]  C. Wahlestedt,et al.  Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers , 1984, Regulatory Peptides.

[15]  T. Hökfelt,et al.  High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man , 1983, Neuroscience Letters.

[16]  B. Fredholm,et al.  Influence of adenosine on the vascular responses to sympathetic nerve stimulation in the canine subcutaneous adipose tissue. , 1983, Acta physiologica Scandinavica.

[17]  T. Neild,et al.  Noradrenergic neuromuscular transmission with special reference to arterial smooth muscle , 1982, Progress in Neurobiology.

[18]  T. Hökfelt,et al.  Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. , 1982, Acta physiologica Scandinavica.

[19]  J. Lundberg,et al.  Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. , 1982, Acta physiologica Scandinavica.

[20]  K. Tatemoto Neuropeptide Y: complete amino acid sequence of the brain peptide. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Hirst,et al.  Evidence for two populations of excitatory receptors for noradrenaline on arteriolar smooth muscle , 1980, Nature.

[22]  P. Hjemdahl,et al.  Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method. , 1979, Life sciences.

[23]  B. Wallin,et al.  The variability of muscle nerve sympathetic activity in resting recumbent man , 1977, The Journal of physiology.

[24]  B. Fredholm Release of adenosine-like material from isolated perfused dog adipose tissue following sympathetic nerve stimulation and its inhibition by adrenergic alpha-receptor blockade. , 1976, Acta physiologica Scandinavica.

[25]  J. Thorson,et al.  Adrenergic transmission at vasoconstrictor nerve terminals partially depleted of noradrenaline. , 1965, Acta physiologica Scandinavica.

[26]  G. Sedvall,et al.  The rate of disappearance of vasoconstrictor responses to sympathetic chain stimulation after reserpine treatment. , 1962, Acta physiologica Scandinavica.

[27]  J. Axelrod,et al.  Effect of decentralization and ganglionic blocking agents on the spontaneous release of H3-norepinephrine. , 1962, The Journal of pharmacology and experimental therapeutics.

[28]  S. Rosell,et al.  The influence of sympathetic adrenergic vasoconstrictor nerves on transport of diffusible solutes from blood to tissues in skeletal muscle. , 1962, Acta physiologica Scandinavica.

[29]  R. Sidman,et al.  Effect of Reserpine on Noradrenaline Content of Innervated and Denervated Brown Adipose Tissue of the Rat , 1962, Nature.

[30]  B. Folkow Impulse frequency in sympathetic vasomotor fibres correlated to the release and elimination of the transmitter. , 1952, Acta physiologica Scandinavica.

[31]  P. Hjemdahl,et al.  Possible involvement of neuropeptide Y in sympathetic vascular control of canine skeletal muscle. , 1988, Acta physiologica Scandinavica.

[32]  P. Hjemdahl Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection. , 1987, Methods in enzymology.

[33]  P. Hjemdahl [63] Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection , 1987 .

[34]  G. Fried,et al.  NPY--a mediator of reserpine-resistant, non-adrenergic vasoconstriction in cat spleen after preganglionic denervation? , 1986, Acta physiologica Scandinavica.

[35]  T. Hökfelt,et al.  Neuropeptide Y and noradrenaline interaction in peripheral cardiovascular control. , 1984, Clinical and experimental hypertension. Part A, Theory and practice.

[36]  A. Carlsson Drugs which block the storage of 5-hydroxytryptamine and related amines , 1966 .

[37]  T. Grahame,et al.  Topographical Anatomy of the Dog , 1943, Nature.